CA Patent

CA2705414A1 — Substituted piperidino-dihydrothienopyrimidines

Assigned to Boehringer Ingelheim International GmbH · Expires 2009-04-23 · 17y expired

What this patent protects

The invention relates to the novel piperidino-dihydrothienopyrimidines of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO2, preferably however SO, and wherein R1, R2, R3 and R4 are defined as in claim 1. The invention also relate…

USPTO Abstract

The invention relates to the novel piperidino-dihydrothienopyrimidines of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO2, preferably however SO, and wherein R1, R2, R3 and R4 are defined as in claim 1. The invention also relates to pharmaceutical compositions containing said compounds. The novel piperidino-dihydrothienopyrimidines are suitable for use in the treatment of respiratory or gastrointestinal disorders or diseases, inflammatory diseases of the joints, the skin or the eyes, diseases of the peripheral or central nervous system or cancers.

Drugs covered by this patent

Patent Metadata

Patent number
CA2705414A1
Jurisdiction
CA
Classification
—
Expires
2009-04-23
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.